Highlights

[Unmet needs] are speed of onset. They are side effects, so across the board – we could talk more about that, and cost if it’s not covered by insurance.

So, for example, Johnson & Johnson, who has come out with the Spravato/esketamine, actually has a very good system in place where they have essentially a company that sorts out that insurance with the patients to get them the best deal. That’s obviously a huge advantage.

The cognition is partly [convincing for Trintellix]. They have some data, they never got FDA labeling for that but the evidence I’ve seen, and I sometimes think I see that just in clinical practice, with Trintellix. The sexual side effects data is not as convincing and also, I haven’t seen it to be differentiated from other serotonin agents.

Well, to be honest they did show efficacy, which is not surprising because AXS-05’s based on bupropion, but I’m not that excited by it. I don’t see a huge benefit or upside